Clinical application and safety observation of levofloxacin in children with refractory Mycoplasma pneumoniae pneumonia
Abstract
Abstract Background In recent years, Mycoplasma pneumoniae (MP) has developed widespread resistance to macrolide antibiotics, and second-line anti-Mycoplasma drugs such as levofloxacin have begun to be used in children. However, there is currently insufficient data on their efficacy and safety. Objective To explore the application effect of levofloxacin in children with refractory Mycoplasma pneumoniae pneumonia (RMPP) and evaluate its safety. Methods This study is an exploratory research, selecting 82 RMPP patients treated with levofloxacin who were admitted to the Department of Pediatric Respiratory Medicine at Weifang People’s Hospital between November 2023 and December 2024 as the research subjects. Compared the blood routine and biochemical indicators before and after the application of levofloxacin, and observed the clinical efficacy and adverse reactions of levofloxacin. Results The average fever reduction time after the application of levofloxacin was (1.96 ± 1.52) days. After the application of levofloxacin, there was no change in white blood cell (WBC), neutrophil (N), platelet (PLT) and other parameters in the blood routine (P > 0.05). The lymphocyte count (L) has increased but remains within the normal range. There was no difference in alanine aminotransferase (ALT) before and after treatment, but aspartate aminotransferase (AST) decreased compared to before. Lactate dehydrogenase (LDH) and creatine kinase isoenzyme (CKMB) decreased after medication (P < 0.05),…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.